Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study
By M. Duijvestein, A. Vos, H. Roelofs, M. Wildenberg, Barbara B. Wendrich, H. Verspaget, E. Kooy-Winkelaar, F. Koning, J. Zwaginga, H. Fidder and 4 more. Gut, 2010
621 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/5a11f848bf12bd196cf8b6465697ccbf1354ba98
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells (2012, neutral): “BM-MSCs isolated from patients with Crohn’s disease were shown to have a similar morphology, phenotype, growth potential, and, most importantly, immunomodulatory capacity compared with BM-MSCs isolated from healthy donors [216,222], suggesting that autologous therapy might be appropriate.”
- Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion (2012, methodology): “ORIGINAL RESEARCH ARTICLE published: 26 September 2012 doi: 10.3389/fimmu.2012.00297 Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion”
- Mesenchymal stromal cells: sensors and switchers of inflammation. (2013, positive): “…homeostasis serves as the basis for their application in disorders resulting from autogeneic or allogeneic immune responses, including Graft-versus- Host Disease (GvHD) and autoimmune disorders (Le Blanc et al., 2008; Duijvestein et al., 2010) and can be referred to as ''stromal cell therapy.''”
- Stem Cell Therapies in Clinical Trials: Progress and Challenges. (2015, background): “The study showed that infusion of donor MSCs from healthy normal patients had little effect on recipient CD parameters, as would be expected (Duijvestein et al., 2010).”
- Mesenchymal stem cells and immunomodulation: current status and future prospects (2016, background): “For example, Duijvestein et al.106 reported that in six patients who received MSC infusions to treat Crohn’s disease, only three exhibited decreased disease activity and in three the diseaseworsened.”
- Ethical and Safety Issues of Stem Cell-Based Therapy (2018, background): “On contrary, adverse effects have been reported in three of nine improved clinical trials [56] that investigated therapeutic potential of intravenously injected MSCs.”
- Clinical Trials with Mesenchymal Stem Cells: An Update (2016, background): “In five of eight MSC-treated patients, Crohn’s disease activity index scores improved, and clinical responses were observed in the other three patients (26).”
- Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials (2012, methodology): “Liang et al, 2011 [36] N N Infusional toxicity+ N Fever+ Organ dysfunction (GI, disease relapse)+ Duijvestein et al, 2010 [30] Y N Infusional toxicity (DMSO allergic reaction, DMSO taste/smell, headache)+ limited Fever+ Organ dysfunction (gastrointestinal– nausea,vomiting, diarrhea, anorexia,…”